Haemonetics Corporation (HAE) is up 17.7% today. Here is some analysis on what might have caused thi

Q1 revenue reached USD 339.38 million versus USD 328.92 million consensus. Haemonetics stock costs E

Q1 revenue reached USD 339.38 million versus USD 328.92 million consensus. Haemonetics stock costs E

Haemonetics Corporation stocks have been trading up by 15.96 percent after strong earnings and robust blood-management demand boosted sentiment. Key Takeaways Citigroup upgraded Haemonetics from Neutral to Buy and lifted its price target to $123, well above the current analyst mean target of $108.40. Shares of HAE jumped about 2.4% after the Citi upgrade and…

Fiscal 2027 guidance remains unchanged at this time. An update on the agreement’s anticipated impact is expected with November 2026 quarterly earnings.

Las acciones de Haemonetics Corporation han subido un 17,46 por ciento en medio de un mayor optimismo por las fuertes ganancias y las perspectivas de crecimiento. Conclusiones clave que los comerciantes deben saber Citigroup actualizó Haemonetics de Neutral a Compra y elevó su precio objetivo de $92 a $123, por encima de la media actual de los analistas.

Investing.com -- Haemonetics Corporation (NYSE:HAE) shares jumped over 17% in premarket trading Thursday following an update on its supply agreement with CSL Plasma Inc.

Haemonetics Corporation stocks have been trading up by 16.93 percent, driven primarily by strong earnings and upbeat analyst upgrades Key Takeaways Citigroup upgraded Haemonetics from Neutral to Buy and raised its price target to $123, well above the prior analyst mean target near $108.40. Shares

Las acciones de Haemonetics Corporation han subido un 17,46 por ciento tras el sentimiento optimista sobre su desempeño de ganancias mejor de lo esperado. Conclusiones clave Citigroup actualizó Haemonetics (HAE) de Neutral a Compra y elevó su precio objetivo a 123 dólares, por encima del objetivo medio actual de los analistas cercano a 108,40 dólares. Citi ve un aumento en las ganancias para HAE a partir de un nuevo suministro no exclusivo de CSL...

Haemonetics Corporation stocks have been trading up by 16.93 percent after upbeat earnings and guidance fueled investor optimism. Key Takeaways Citigroup/Citi upgraded Haemonetics from Neutral to Buy and raised its price target to $123, above the current analyst mean target of $108.40. Citi expects earnings upside from a new non-exclusive supply agreement with CSL, estimating…

Haemonetics Corporation stocks have been trading up by 15.96 percent after strong earnings and upbeat guidance bolstered investor confidence. Key Takeaways Citigroup upgraded Haemonetics from Neutral to Buy and hiked its price target to $123, well above the prior Street average near $108.40. Shares

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Haemonetics stock heads toward November 5 results after fiscal Q1 revenue reached USD 339.38 million